Biotech Analyst Blum, along with Ross Pierce, a consultant with 34 years of clinical and regulatory experience at the FDA, discuss potential key points expected in the upcoming FDA Advisory Committee forGeron’s Imetelstat on an Analyst/Industry conference call to be held on March 11 at 2 pm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GERN: